São Paulo School of Advanced Sciences on Neglected Diseases Drug Discovery – focus on Kinetoplastids |
A SPSAS-ND3 foi realizada de 14 a 24 de junho de 2015 no campus do Centro Nacional de Pesquisa em Energia e Materiais (CNPEM), em Campinas (SP).
A Escola, organizada pelo Laboratório Nacional de Biociências (LNBio) e financiada pela FAPESP, contemplou aspectos multidisciplinares do processo de descoberta de fármacos aplicados à doença de Chagas, leishmaniose e à tripanossomíase africana humana.
A SPSAS-ND3 abordou desde conceitos básicos da ciência de descoberta de fármacos até as investigações de ponta desenvolvidas nesta área.
Dentre os grandes temas da programação, destacam-se: high throughput screening (HTS) e high content screening (HCS); biologia estrutural e screening virtual; análises de dados de triagens; química medicinal; otimização de leads; absorção, distribuição, metabolismo e excreção (ADME) in vitro e in vivo; e modelos animais para estudos de farmacocinética e estudos de eficácia.
-
Instituição
Laboratório Nacional de Biociências / CNPEM / MCTI
-
Área de conhecimento
Química
-
Pesquisador Responsável
Lucio Holanda Gondim de Freitas Junior
-
Nº do Processo FAPESP
2013/50644-4
-
Período
14/06/2015 a 24/06/2015
-
Inscrições
Encerradas
-
Site
-
Cidade
Campinas
-
Palavras-chave
Fármacos, Doenças negligenciadas, Saúde, Química, Biociências
-
Programa
Ocultar
June, 14th
13:00 –15:00: Lunch and Registration
15:00 –16:00: Groups division: Organizing Committee
16:00 – 6:30: Coffee-break
16:30 –17:30: Welcoming and General RemarksJune, 15th
08:20 – 08:45: Overview of SPSAS-ND3: dynamics and expected outcomesDr. Lucio Freitas-Junior – LNBio/ Brazil
08:45 – 09:30: Neglected Tropical Diseases: Needs and Current Drug Discovery LandscapeDr. Eric Chatelain – DNDi/ Switzerland
09:30 – 10:00: Drug Discovery: The Pharmaceutical Industry PerspectiveDr. Sheraz Gul – ScreeningPort Fraunhofer/ Germany
10:00 – 10:45: Introduction to Drug Discovery/Design of Biochemical Assays for Drug Discovery Purposes – what can be achieved and learnings from past success and failuresDr. Sheraz Gul – ScreeningPort Fraunhofer/ Germany
10:45 – 11:15: Coffee-break
11:15 – 12:00: Identification of metabolic targets in trypanosomatidsDr. Artur Cordeiro - LNBio/ Brazil
12:00 – 12:45: Virtual ScreeningDr. Rafael Guido – USP/ Brazil
13:00 – 14:10: Lunch
14:10 – 14:40: Poster fixation
14:40 – 15:30: Biosafety in level II laboratory/ Instructions for practical activitiesDr. Carolina Borsoi / Dr. Vanessa Fontana
15:30 – 16:00: Official photography
16:00 – 16:50: Coffee-break
16:50 – 17:10: Opening ceremonyDr. Kleber Franchini - LNBio/ Brazil
17:10 – 17:30: Opening ceremonyEric Stobbaerts - DNDi Latin America
17:30 – 17:50: Inaugural ClassProf. Michel Rabinovitch – Unifesp/Brazil
17:50-19:50: Poster session I/ Opening cocktail: Brazilian eveningSupported by DNDi
June, 16th
08:30 – 09:15 Screening jargon and termsDr. Sheraz Gul – ScreeningPort Fraunhofer/ Germany
09:15 – 10:00 HTS Assay DesignDr. Sheraz Gul – ScreeningPort Fraunhofer/ Germany
10:00 - 10:45 Biochemistry of Kinetoplastids and Drug DiscoveryProf. Sergio Schenkman - UNIFESP/ Brazil
10:45 – 11:15 Coffee-break
11:15 – 12:00 Drug targets in Trypanosomes
Prof. Joana Tavares – Universidade do Porto/ Portugal
12:00 – 12:45 Current Chemotherapy for leishmaniasis: Drug Mechanism of ActionProf. Simon Croft - LSHTM/UK
13:00 – 14:10 Lunch
14:10 – 16:10 Practice I – Biochemical Assays
Module 1 – Protease assay development and validation- Dr. Sheraz Gul – Group A and B – Room 09LNBioModule 2 – High throughput binding screening using MicroScale Thermophoresis - Nanotemper – GroupC and D –Room 22 LNBioModule 3 – Using LabWare LIMS/ELN to catalogue Chemical Structures & ELN (Electronic LaboratoryNotebook) Workshop - LabWare – Group E and F – Room 69 LNBioModule 4 – Fluorescence intensity assay for Trypanosoma brucei viability using CLARIOStar – Photonics/Dr. Bruno Pascoalino – Group G and H – Room 42 LNBio
16:10 – 16:30 Coffee-break
16:30 – 18:30 Practice I – Biochemical Assays
Module 1 – Protease assay development and validation - Dr. Sheraz Gul – Group C and D - Room 09LNBioModule 2 – High throughput binding screening using MicroScale Thermophoresis - Nanotemper – GroupE and F– Room 22 LNBioModule 3 – Using LabWare LIMS/ELN to catalogue Chemical Structures & ELN (Electronic LaboratoryNotebook) Workshop - LabWare – Group G and H – Room 69 LNBioModule 4 – Fluorescence intensity assay for Trypanosoma brucei viability using CLARIOStar – Photonics/Dr. Bruno Pascoalino – Group A and B – Room 42 LNBio
June, 17th
08:30 – 09:15 The Path to a Candidate: A multidisciplinary Effort and a Lot of HurdlesDr. Eric Chatelain - DNDi/ Switzerland
09:15 – 10:00 High Throughput and High Content Screening for TrypanosomesProf. Vicky M Avery - Eskitis Institute/Griffith University/ Australia
10:00 - 10:45 MiRNA screening for drug discoveryDr. Musa Mhlanga – University of Cape Town & CSIR & IMM/ South Africa
10:45 – 11:15 Coffee-break
11:15 – 12:00 Integrative Drug Discovery Programs
Dr. Sheraz Gul – ScreeningPort Fraunhofer/ Germany
12:00 – 12:45 HCS Data Analysis and ReductionDr. Kamyar Hadian - Helmholtz Zentrum München/ Germany
13:00 – 14:10 Lunch
14:10 – 16:10 Practice I – Biochemical Assays
Module 1 – Protease assay development and validation - Dr. Sheraz Gul – Group E and F- Room 09LNBioModule 2 – High throughput binding screening using MicroScale Thermophoresis - Nanotemper – GroupG and H– Room 22 LNBioModule 3 – Using LabWare LIMS/ELN to catalogue Chemical Structures & ELN (Electronic LaboratoryNotebook) Workshop - Labware – Group A and B – Room 69 LNBioModule 4 – Fluorescence intensity assay for Trypanosoma brucei viability using CLARIOStar – Photonics/Dr. Bruno Pascoalino – Group C and D – Room 42 LNBio
16:10 – 16:30 Coffee-break
16:30 – 18:30 Practice I – Biochemical Assays
Module 1 – Protease assay development and validation - Dr. Sheraz Gul – Group G and H- Room 09LNBioModule 2 – High throughput binding screening using MicroScale Thermophoresis - Nanotemper – GroupA and B– Room 22 LNBioModule 3 – Using LabWare LIMS/ELN to catalogue Chemical Structures & ELN (Electronic LaboratoryNotebook) Workshop - Labware – Group C and D – Room 69 LNBioModule 4 – Fluorescence intensity assay for Trypanosoma brucei viability using CLARIOStar – Photonics/Dr. Bruno Pascoalino – Group E and F – Room 42 LNBio
18:30 – 20:30 Poster session II/ Pastel eveningSupported by DNDi
June, 18th
08:30 – 09:15 Screening Databases, Hit Clustering and PrioritizationDr. Jean-Robert Ioset – DNDi/ Switzerland
09:15 – 10:00 Host-Parasite Interactions at the Cellular LevelProf. Renato Mortara - UNIFESP/ Brazil
10:00 - 10:45 Genetic Diversity of KinetoplastidsProf. Bianca Zingales - USP/ Brazil
10:45 – 11:15 Coffee-break
11:15 – 12:00 Secondary Assays for Hit-to-Lead and Lead PrioritizationDr. Carolina B. Moraes – LNBio/ Brazil
12:00 – 12:45 Recent advances in HCS technologiesDr. Kamyar Hadian - Helmholtz Zentrum München/ Germany
13:00 – 14:10 Lunch
14:10 – 16:10 Practice II – HCS/ Data Analysis
Module 1 – High Content Screening in Neglected Diseases Research: the Basics – Dr.Kaliandra deAlmeida Gonçalves/ Dr. Carolina Borsoi – Group A and B – Room 09 LNBioModule 2 – Phenotypic Antiparasitic Screening Data Analysis and Visualization – Dr. Sheraz Gul/ Dr.Kamyar Hadian – Group C and D – Room 69 LNBioModule 3 – Tools for HTS Data Analysis and Visualization - Dr. Jair L. Siqueira-Neto - Group E and F–Room 201 LNLSModule 4 – Screening Hit Analysis and Clustering/Screening Data Sharing – Dr. Jean-Robert Ioset –Group G and H – Room 227 B CTBE
16:10 – 16:30 Coffee-break
16:30 – 18:30 Practice II – HCS/ Data Analysis
Module 1 –High Content Screening in Neglected Diseases Research: the Basics – Dr. Kaliandra deAlmeida Gonçalves/ Dr. Carolina Borsoi - Group C and D – Room 09 LNBioModule 2 – Phenotypic Antiparasitic Screening Data Analysis and Visualization – Dr. Sheraz Gul/ Dr.Kamyar Hadian – Group E and F – Room 69 LNBioModule 3 – Tools for HTS Data Analysis and Visualization - Dr. Jair L. Siqueira-Neto - Group G and H–Room 201 LNLSModule 4 – Screening Hit Analysis and Clustering/Screening Data Sharing – Dr. Jean-Robert Ioset –Group A and B – Room 227 B CTBE
June, 19th
08:30 – 09:15 Medicinal Chemistry: An IntroductionDr. Tom Von Geldern/ USA
09:15 – 10:00 Assessing Physicochemical and ADME Properties in Early Drug DiscoveryProf. Susan Charman –Monash Univ/ Australia
10:00 - 10:45 Issues Related to Drug Development in Kinetoplastid DiseasesProf. Simon Croft – LSHTM/UK
10:45 – 11:15 Coffee-break
11:15 – 12:00 Pharmacokinetics Properties to Ensure Efficacy and SafetyProf. Susan Charman –Monash Univ/ Australia
12:00 – 12:45 Compound Safety Profiling: in silico, in vitro and in vivoDr. Tom Von Geldern/ USA
13:00 – 14:10 Lunch
14:10 – 16:10 Practice II – HCS/ Data Analysis
Module 1 – High Content Screening in Neglected Diseases Research: the Basics – Dr. Kaliandra deAlmeida Gonçalves/ Dr. Carolina Borsoi – Group E and F– Room 09 LNBioModule 2 – Phenotypic Antiparasitic Screening Data Analysis and Visualization – Dr. Sheraz Gul/ Dr.Kamyar Hadian – Group G, H, A and B – Room 69 LNBioModule 3Module 4 – Screening Hit Analysis and Clustering/Screening Data Sharing – Dr. Jean-Robert Ioset –Group C and D – Room 227 B CTBE
16:10 – 16:30 Coffee-break
16:30 – 18:30 Practice II – HCS/ Data Analysis
Module 1 – High Content Screening in Neglected Diseases Research: the Basics – Dr. Kaliandra deAlmeida Gonçalves/ Dr. Carolina Borsoi – Group G and H– Room 09 LNBioModule 2Module 3 - Tools for HTS Data Analysis and Visualization - Dr. Jair L. Siqueira-Neto - Group A, B, C andD– Room 69 LNBioModule 4 - Screening Hit Analysis and Clustering/Screening Data Sharing – Dr. Jean-Robert Ioset –Group E and F – Room 227 B CTBE
18:30 – 20:30 Poster session III/ Pizza evening
Supported by DNDi
June, 20th
08:30 – 09:15 Think Medicinal ChemistryDr. Gilles Courtemanche– Bioaster/ France
09:15 – 10:00 Lead Optimization Program for Chagas disease: An ExampleMartine Keenan – Epichem/ Australia
10:00 - 10:45 Building a National Consortium on Neglected Diseases Drug DiscoveryDr. Lucio Freitas-Junior – LNBio/ Brazil
10:45 – 11:15 Coffee-break
11:15 – 11:50 Synthesis and Biological Activity of Natural Products and DerivativesProf. Dr. Ronaldo Pilli - UNICAMP/ Brazil
11:50 – 12:25 New Synthetic Tools for the Construction of Molecules of Medicinal ValueProf. Dr. Carlos R.D. Correia – UNICAMP/ Brazil
12:25 – 14:00 Lunch
14:00 – 14:35 Fluorescent Tags and Probes: Mechanisms of Actions and Dynamics in Live Cells of BioactiveSmall MoleculesDr. Brenno Neto - UNB/ Brazil
14:35 – 15:10 Hypervalent Iodine in Synthetic Organic ChemistryDr. Luiz Fernando Silva Jr-USP/Brazil
15:10 – 15:45 Developing a library of heterocycles to fight neglected diseasesDr. Flavio da Silva Emery- USP/Brazil
15:45 -16:15 Coffee-break
16:15 – 17:15 Round-table
17:30 – 22:00 Social gathering: Festa Junina (Typical Brazilian Festival)
June, 21th
08:00 – 10:00 Practice III: In vitro and In vivo ADME/Medicinal Chemistry Problem Solving
Module 1 – Hit to Lead - Dr. Gilles Courtemanche Group A and B – Room 111 B CTBEModule 2 –- Lead Optimization – Dr. Martine Keenan/ Dr. Tom Von Geldern -Group C and D– Room 227B CTBEModule 3 – In vitro metabolic stability and metabolic profile – Daniel Lebre – Group E and F– Room 22LNBioModule 4 – Drug Candidates: Bioanalytical Validation and In vivo Pharmacokinetic Studies. Dr. SilvanaA. Rocco/Raphael Morales - Group G and H– Room 69 LNBio
10:00 – 10:15 Coffee-break
10:15 – 12:15 Practice III: In vitro and In vivo ADME/Medicinal Chemistry Problem Solving
Module 1 – Hit to Lead - Dr. Gilles Courtemanche Group C and D– Room 111 B CTBEModule 2 – Lead Optimization – Dr. Martine Keenan/ Dr. Tom Von Geldern – Group E and F– Room 227B CTBEModule 3 – In vitro metabolic stability and metabolic profile – Daniel Lebre - Group G and H– Room 22LNBioModule 4 – Drug Candidates: Bioanalytical Validation and In vivo Pharmacokinetic Studies.- Dr. SilvanaA. Rocco/Raphael Morales – Group A and B– Room 69 LNBio
12:15 – 13:45 Lunch
13:45 – 15:45 Practice III: In vitro and In vivo ADME/Medicinal Chemistry Problem Solving
Module 1 – Hit to Lead - Dr. Gilles Courtemanche – Group E and F– Room 111 B CTBEModule 2 – Lead Optimization – Dr. Martine Keenan/ Dr. Tom Von Geldern – Group G and H– Room 227B CTBEModule 3 – In vitro metabolic stability and metabolic profile – Daniel Lebre – Group A and B– Room 22LNBioModule 4 – Drug Candidates: Bioanalytical Validation and In vivo Pharmacokinetic Studies.- Dr. SilvanaA. Rocco/Raphael Morales – Group C and D– Room 69 LNBio
15:45 – 16:15 Coffee-break
16:15 – 18:15 Practice III: In vitro and In vivo ADME/Medicinal Chemistry Problem Solving
Module 1 – Hit to Lead - Dr. Gilles Courtemanche - Group G and H– Room 111 B CTBEModule 2 – Lead Optimization – Dr. Martine Keenan/ Dr. Tom Von Geldern – Group A and B– Room 227B CTBEModule 3 – In vitro metabolic stability and metabolic profile – Daniel Lebre – Group C and D– Room 22LNBioModule 4 – Drug Candidates: Bioanalytical Validation and In vivo Pharmacokinetic Studies.- Dr. SilvanaA. Rocco/Raphael Morales – Group E and F– Room 69 LNBio
June, 22th
08:30 – 09:15 Drug Efficacy Models for Chagas DiseaseProf. John Kelly – LSHTM/UK
09:15 – 10:00 Animal Models of Leishmaniasis Applied to Drug DiscoveryProf. Silvia Uliana - USP/ Brazil
10:00 - 10:45 Drug Efficacy Models for Leishmaniasis and HATProf. Joana Tavares – Universidade do Porto/ Portugal
10:45 – 11:15 Coffee-break
11:15 – 12:00 Pre-clinical Pharmacology: How to Take a Lead Compound to Clinical StudiesProf. João Batista Calixto - UFSC/ Brazil
12:00 –12:45 Virulence Factors in Visceral LeishmaniasisProf. Carlos Henrique Nery Costa - UFPI/ Brazil
13:00 – 14:10 Lunch
14:10 –16:10 Practice IV: Animal models
Module 1 – Chagas Disease: from bench to trench – Dr. Ana Torrecilhas – Group A and B – Room 09LNBioModule 2 – VL hamster model for Drug Efficacy – Dr. Andre Tempone - Group C and D - Room 22 LNBioModule 3 – Bioluminescence imaging of Kinetoplastid infections – Dr. John Kelly/Dr. Joana Tavares –Group E and F - Room 09 LNBioModule 4 – Guided tour – Group G and H – LNBio entrance
16:10 –16:30 Coffee-break
16:30 –18:30 Practice IV: Animal models
Module 1 – Chagas Disease: from bench to trench – Dr. Ana Torrecilhas - Group C and D– Room 09LNBioModule 2 – VL hamster model for Drug Efficacy – Dr. Andre Tempone – Group E and F - Room 22 LNBioModule 3 – Bioluminescence imaging of Kinetoplastid infections – Dr. John Kelly/Dr. Joana Tavares –Group G and H - Room 09 LNBioModule 4 – Guided tour – Group A and B– LNBio entrance
June, 23th
08:30 – 12:45 CLOSING SESSION: Brazilian Pharma: how it can actively drive neglected diseases drugdiscovery?Chair: Prof. João Batista Calixto – UFSC/ Brazil
08:30 – 08:45 Prof. João Batista Calixto– UFSC/ Brazil
08:45 – 09:15 Dr. Kleber Franchini – Brazilian Biosciences National Laboratory (LNBio) / Brazil
09:15 - 09:45 André Berto Gimenez – Brazilian Innovation Agency (FINEP) / Brazil
09:45 - 10:15 Pedro Palmeira – Brazilian Development Bank (BNDES) / Brazil
10:15 - 10:45 Simone Godoi – São Paulo Research Foundation (FAPESP) / Brazil
10:45 – 11:15 Coffee-break
11:15 – 11:45 Cristalia: A History of Research, Development and InnovationProf. Dr. Spartaco Astolfi Filho – Cristalia/ Brazil
11:45 – 12:15 Eric Chatelain - DNDi/ Switzerland
12:15 – 12:45 Round table
13:00 – 14:10 Lunch
14:10-16:10 Practice IV: Animal models
Module 1 – Chagas Disease: from bench to trench – Dr. Ana Torrecilhas – Group E and F– Room 09LNBioModule 2 – VL hamster model for Drug Efficacy – Dr. Andre Tempone – Group G and H - Room 22 LNBioModule 3 – Bioluminescence imaging of Kinetoplastid infections – Dr. John Kelly/Dr. Joana Tavares–Group A and B- Room 09 LNBioModule 4 – Guided tour – Group C and D– LNBio entrance
16:10 – 16:30 Coffee-break
16:30 – 18:30 Practice IV: Animal models
Module 1 – Chagas Disease: from bench to trench – Dr. Ana Torrecilhas – Group G and H– Room 09LNBioModule 2 – VL hamster model for Drug Efficacy – Dr. Andre Tempone – Group A and B - Room 22 LNBioModule 3 – Bioluminescence imaging of Kinetoplastid infections – Dr. John Kelly/Dr. Joana Tavares –Group C and D- Room 09 LNBioModule 4 – Guided tour – Group E and F– LNBio entrance
19:00 Closing dinner
June, 24th
09:15 – 10:40 Feedback10:40 – 11:00 Closing remarks
-
-
Notícias
Relacionadas Para avançar na descoberta de fármacos, Brasil precisa fortalecer química medicinal
Agência FAPESP, 24 de junho de 2015
Escola abordará descoberta de fármacos contra doenças negligenciadas
Agência FAPESP, 05 de fevereiro de 2015
Sao Paulo School of Advanced Science on Neglected Diseases Drug Discovery
Agência FAPESP, 08 de janeiro de 2015
-
-
Próximas
ESPCAs -
ESPCAs
Realizadas